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Letters to the Editor 
Dear Editor 
Inhaled beclomethasone dipropionate 
symposium 
We have read with great interest in a recent Respiratory 
Medicine supplement (1998, volume 92, Supplement A) the 
series of papers presented at a symposium on inhaled 
beclomethasone dipropionate (BDP). These papers all 
describe a novel formulation (Qvar, 3M Healthcare) of 
BDP containing hydrofluoroalkane-134a (HFA-134a), 
which has been developed in response to the banning of 
chlorofluorocarbon propellants under the Montreal 
Protocol. The clinical efficacy data on Qvar, notably the 
study by Davies et al. (1) provide the basis for the use of 
lower BDP doses when given as the Qvar formulation to 
achieve a given anti-asthma response, while Qvar had less 
effect on the HPA axis than the CFC formulation (2). 
These findings could be predicted qualitatively on the 
basis of a higher fine particle fraction and higher lung 
deposition for Qvar. However, the lung deposition data (3) 
show the remarkable result that only 4% of the delivered 
(ex-actuator) dose is deposited in the lungs for a CFC- 
formulation of BDP, while 51% of the dose is deposited in 
the lungs for the HFA formulation. It is debatable which of 
these two deposition figures is the more surprising. Mean 
lung deposition with correct inhaler technique has been 
shown to vary considerably according to formulation (4), 
but no other mean lung deposition data for inhaled asthma 
products delivered from pressurized metered dose inhalers 
without spacer devices, and inhaled correctly, are as low as 
4% or as high as 5 1% of the delivered dose. It must be borne 
in mind that these deposition values are both expressed as 
percentages of the ex-actuator dose, and that they can only 
be compared directly if the ex-actuator doses for the two 
products are the same, which may well not be the case in 
this instance. 
Attention to technical issues is essential if accurate lung 
deposition data are to be obtained. Scintigraphic studies 
are customarily performed using the radionuclide ggmT~, 
which is physically associated with the drug particles or 
droplets. As an essential prerequisite to the scintigraphic 
study itself, in vitro validation measurements are carried out 
using a particle sizing device such as an Andersen sampler, 
to show that the drug and radiolabel are associated together 
in particles or droplets of different sizes. Once this has been 
demonstrated, it may be assumed that the quantification of 
the radiolabel distribution will effectively quantify deposi- 
tion of the drug itself. There are no validation data pre- 
sented in Leach’s paper (3), but validation data have been 
provided previously for the HFA formulation (5), showing 
a good agreement between the drug distribution before 
labelling, the drug distribution after labelling, and the 
distribution of the radiolabel. Cross-reference is made to an 
earlier abstract as the source of validation data for the CFC 
formulation (6), but this abstract only provides data com- 
paring drug distributions before and after labelling, and 
does not compare radiolabel and drug distributions. To the 
best of our knowledge, no full published validation data 
comparing drug and radiolabel distributions have been 
presented for the CFC product, other than those appearing 
in the earlier paper by Leach (5). These data (Figure 4 of 
Leach’s 1996 paper) showed a marked mismatch between 
drug and radiolabel distributions for the CFC formulation. 
One way of quantifying similarities or differences between 
drug and radiolabel distributions is to extrapolate from the 
approach used to show the similarities or differences 
between two dissolution curves for orally administered 
products (7) where the United States Food and Drug 
Administration recommend that an ‘F-2’ statistic is calcu- 
lated. Two distributions are deemed to be similar if F-2 is 
>50. We have applied this approach to drug and radiolabel 
distribution data generated in validation experiments, and 
have found that distributions which match show an F-2 
value between 60 and 100 (unpublished observations). An 
analysis of the data in figure 4 from the paper by Leach (5) 
provides an F-2 value of about 40. Curiously, Leach (3) 
comments in his discussion that he has ‘great confidence’ in 
his results, while going on to say that because of labelling 
problems the CFC data are ‘less precise’ than the HFA 
data. 
In his studies, Leach (3) has made no correction to the 
data obtained for either CFC or HFA product to allow for 
the effects of overlying tissue on the attenuation of the 
gamma ray count reaching the gamma camera. We have 
shown that failure to allow for the effects of tissue 
attenuation causes lung deposition to be significantly 
underestimated (8). It has been claimed that no validated 
method exists for making a tissue attenuation correction, 
but this is incorrect. There are at least three methods which 
can be used to make this correction, involving transmission 
scanning (9) injection of a known amount of 99mTc-macro- 
aggregated albumin as a calibration dose (lo), and the use 
of correction factors based upon individual body thickness 
measurements (11). We compared these methods (S), and 
showed that providing an appropriate tissue attenuation 
correction is made, it is possible to quantify the deposition 
of a known amount of radionuclide in the lungs to within 
about 5% of the true figure. Lung deposition data agreeing 
with those obtained by a second independent method may 
be obtained (12), assuming a tissue attenuation correction 
is applied to the scintigraphic data. Since different sites 
(lungs, stomach and oropharynx) attenuate gamma rays to 
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different extents, it becomes especially important to make 
corrections for tissue attenuation when the relative amounts 
of lung and oropharyngeal deposition are expected to be 
different for the two products, and it will not be satisfactory 
to make no correction on the basis that subjects act as their 
own controls. In addition, failure to correct for tissue 
attenuation will produce data that cannot be compared 
directly with those obtained elsewhere for other products. 
Based upon the above considerations, it is probable that 
the 13-fold difference in lung deposition values between 
CFC and HFA products reported by Leach (3) is caused in 
part by inaccurate quantification of the data, especially for 
the CFC product. Earlier this year, a workshop was held in 
London under the auspices of the British Association for 
Lung Research, which set out guidelines to ensure the 
correct conduct of scintigraphic studies in terms of their 
design and technical aspects, and to allow data obtained in 
different scintigraphic centres to be compared more readily. 
Amongst these guidelines was the need to generate and 
display adequate radiolabelling validation data for all 
products tested, and the need to make corrections for the 
effects of tissue attenuation of gamma rays. The workshop 
report has been published in Respiratory Medicine (13). 
There are plans to revisit these issues at another workshop 
to be held as part of the international Society for Aerosols 
in Medicine bi-annual congress in Vienna in June 1999. 
The clinical response to inhaled corticosteroids is very 
difficult to measure: since these drugs act over relatively 
long time periods, and have flat dose response curves. The 
quantification of lung deposition data for inhaled asthma 
drugs can serve as a valuable surrogate for clinical 
response, but only providing that the technical issues 
associated with quantification of the deposition data have 
been addressed appropriately. 
S. P. NEWMAN, MD AND G. R. PITCAIRN, MD 
Pharmaceutical Pvojles, Highfields Science Park, 
University Botaleuavd, Nottingham, NGi’ ,?.QP, U.K. 
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Reply to Drs Newman and Pitcairn 
We have read the ‘Letter to the Editor’ tendered by 
Drs Newman and Pitcairn regarding our paper in 
Respbatory Medicine (1), and we offer the following 
response. Dr Newman refers to the fact that detailed 
technical support of some of the data presented was not 
provided in the manuscript. The articles published in the 
supplement represent verbal overviews of many clinical 
studies presented in a symposium at the 1997 European 
Respiratory Society Meeting in Berlin. As such, the detailed 
experimental methods of all of the studies cited would have 
required several volumes of Respiratory Medicine to 
present. Obviously this is well beyond the scope or intention 
of the Supplement. Dr Newman has therefore chosen to go 
back to abstracts that represent a small portion of the work 
presented and criticize the techniques. Complete details of 
two of the studies cited in the symposium are presented in a 
recent article published in the European Respiratory Journal 
(2) and many of the issues raised are addressed there. 
However, the authors would like to address the specific 
questions raised here. 
The authors agree that the essential element of any 
radiolabelled deposition study is the validation of the 
association of the radiolabel with the drug. Toward 
that end, the authors developed the Andersen Impactor 
